VPIM
XENE icon

Vanguard Personalized Indexing Management’s Xenon Pharmaceuticals XENE Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509K Buy
8,761
+4,228
+93% +$195K 0.01% 1298
2025
Q4 		$203K Buy
+4,533
New +$190K ﹤0.01% 1718

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Personalized Indexing Management's XENE Position: Q1 2026 in Review

Vanguard Personalized Indexing Management increased its Xenon Pharmaceuticals (XENE) stake by 93% in Q1 2026, buying an estimated $195K and bringing the position to 8,761 shares worth $509K. The position accounts for 0.01% of the portfolio, ranked #1298.

Vanguard Personalized Indexing Management first reported a position in XENE in Q4 2025 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Vanguard Personalized Indexing Management held 8,761 shares of Xenon Pharmaceuticals worth $509K as of Q1 2026.
  • Vanguard Personalized Indexing Management bought 4,228 Xenon Pharmaceuticals shares in Q1 2026, an estimated $195K.
  • Xenon Pharmaceuticals made up 0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #1298 holding.
  • Vanguard Personalized Indexing Management first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.